X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
schedule dependence (15) 15
oncology (12) 12
humans (11) 11
animals (9) 9
drug administration schedule (8) 8
pharmacology & pharmacy (8) 8
mice (7) 7
antineoplastic agents - administration & dosage (5) 5
chemotherapy (5) 5
male (5) 5
5-fluorouracil (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
cell line, tumor (4) 4
cell survival - drug effects (4) 4
deoxycytidine - administration & dosage (4) 4
deoxycytidine - analogs & derivatives (4) 4
dose-response relationship, drug (4) 4
female (4) 4
pharmacokinetics (4) 4
toxicity (4) 4
antineoplastic agents - pharmacokinetics (3) 3
cancer (3) 3
cisplatin (3) 3
colonic neoplasms - drug therapy (3) 3
dna (3) 3
drug screening assays, antitumor (3) 3
gemcitabine (3) 3
infusion (3) 3
neoplasms, experimental - drug therapy (3) 3
schedule-dependence (3) 3
time factors (3) 3
adolescent (2) 2
adult (2) 2
antimetabolites, antineoplastic - administration & dosage (2) 2
antimetabolites, antineoplastic - pharmacokinetics (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic agents - pharmacology (2) 2
antineoplastic agents - therapeutic use (2) 2
antitumor-activity (2) 2
apoptosis - drug effects (2) 2
biochemistry & molecular biology (2) 2
breast cancer (2) 2
breast-cancer (2) 2
carcinoma (2) 2
carcinoma, non-small-cell lung - drug therapy (2) 2
cell cycle - drug effects (2) 2
child (2) 2
child, preschool (2) 2
combination (2) 2
deoxycytidine - pharmacokinetics (2) 2
dependence (2) 2
drug interaction (2) 2
drug resistance (2) 2
fluorouracil (2) 2
fluorouracil - administration & dosage (2) 2
haematological toxicity (2) 2
in-vitro (2) 2
index medicus (2) 2
invivo (2) 2
kinetics (2) 2
leukemia (2) 2
lung neoplasms - drug therapy (2) 2
mice, inbred c57bl (2) 2
mice, inbred strains (2) 2
models (2) 2
models, biological (2) 2
neoplasm transplantation (2) 2
organoplatinum compounds - administration & dosage (2) 2
oxaliplatin (2) 2
paclitaxel (2) 2
pharmacology (2) 2
randomized trial (2) 2
rats (2) 2
rats, sprague-dawley (2) 2
schedules (2) 2
stimulation (2) 2
taxol (2) 2
therapy (2) 2
tumor cells, cultured - drug effects (2) 2
tumor-cells (2) 2
10-deaza-aminopterin series (1) 1
13-cis-retinoic acid (1) 1
1st-line treatment (1) 1
2',2'-difluorodeoxycytidine (1) 1
6-mercaptopurine (1) 1
6-thioguanine (1) 1
adaptive systems (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - pathology (1) 1
adjuvant bevacizumab (1) 1
administration, metronomic (1) 1
administration, oral (1) 1
adriamycin (1) 1
aging - physiology (1) 1
algorithms (1) 1
allografts (1) 1
amifostine (1) 1
analysis (1) 1
angiogenesis inhibitors - administration & dosage (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Letters, ISSN 0304-3835, 2017, Volume 400, pp. 293 - 304
Abstract We present a rationale for further clinical development and assessment of metronomic chemotherapy on the basis of unexpected results obtained in... 
Hematology, Oncology and Palliative Medicine | Animal models | Metastasis | Metronomic chemotherapy | Antiangiogenesis | Immunotherapy | Vessel co-option | EFFICACY | LOW-DOSE CYCLOPHOSPHAMIDE | TUMOR-REGRESSION | MODEL | SCHEDULE-DEPENDENCE | BREAST-CANCER | RESPONSES | THERAPY | ONCOLOGY | ADJUVANT BEVACIZUMAB | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Administration, Metronomic | Humans | Neovascularization, Pathologic | Antineoplastic Combined Chemotherapy Protocols - toxicity | Neoplasms, Experimental - pathology | Xenograft Model Antitumor Assays | Angiogenesis Inhibitors - administration & dosage | Neoplasm Metastasis | Animals | Angiogenesis Inhibitors - toxicity | Time Factors | Tumor Burden - drug effects | Cell Line, Tumor | Mice | Neoplasms, Experimental - drug therapy | Neoplasms, Experimental - blood supply | Antimitotic agents | Medical research | Chemotherapy | Endothelial growth factors | Genetically modified organisms | Stem cells | Medicine, Experimental | Genetic engineering | Antineoplastic agents | Cancer | Drugs | Biotechnology | Adaptive systems | Toxicity | Syngeneic grafts | Medical services | Clinical trials | Stem cell transplantation | Stimulation | Drug delivery | Malignancy | Cancer therapies | Immunosuppressive agents | Anticancer properties | Metastases | Allografts | Historical account | Rodents | Xenografts | Vascular endothelial growth factor | Drug dosages | Immune system | Lymphatic system | Breast cancer | Brain research | Lungs | Antiangiogenics | Cell lines | Biomarkers | Trastuzumab | Tumors | Index Medicus
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 02/2009, Volume 20, Issue 2, pp. 123 - 130
Journal Article
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 2005, Volume 25, Issue 1, pp. 163 - 173
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 11/2000, Volume 56, Issue 8, pp. 567 - 574
Objective: DMDC (2'-deoxy-2'-methylidenecytidine) is a potential antitumour deoxycytidine analogue of cytosine arabinoside. The major dose-limiting toxicity of... 
Pharmacology/Toxicology | Biomedicine | DMDC Schedule dependence Haematological toxicity | DMDC | Haematological toxicity | Schedule dependence | 5-FLUOROURACIL | KINETICS | schedule dependence | PHARMACOLOGY & PHARMACY | CELL | haematological toxicity | Lung Neoplasms - drug therapy | Neutrophils - cytology | Humans | Antineoplastic Agents - administration & dosage | Deoxycytidine - pharmacokinetics | Antineoplastic Agents - adverse effects | Blood Platelets - cytology | Colorectal Neoplasms - drug therapy | Deoxycytidine - adverse effects | Antineoplastic Agents - pharmacokinetics | Leukocyte Count | Blood Platelets - drug effects | Neutropenia - chemically induced | Leukocytes - cytology | Cell Survival - drug effects | Hematologic Diseases - chemically induced | Drug Administration Schedule | Colorectal Neoplasms - blood | Deoxycytidine - administration & dosage | Neutrophils - drug effects | Platelet Count | Body Fluid Compartments | Hematologic Diseases - blood | Models, Biological | Carcinoma, Non-Small-Cell Lung - blood | Leukocytes - drug effects | Lung Neoplasms - blood | Carcinoma, Non-Small-Cell Lung - drug therapy | Deoxycytidine - analogs & derivatives | Models | Cytarabine | Depression, Mental | Analysis | Drug therapy | Toxicity | Cell survival | cytosine arabinoside | Bone marrow | Data processing | Depression | Leukocytes (neutrophilic) | Differentiation | Platelets | Neutropenia
Journal Article
Journal of Orthomolecular Medicine, ISSN 0317-0209, 03/2007, Volume 22, Issue 1, pp. 21 - 26
Journal Article
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 10/1988, Volume 114, Issue 5, pp. 509 - 513
Doxorubicin serum elimination kinetics were measured by HPLC in three different patient groups. A dose of (a) 30 mg/m2; (b) 50 mg/m2, and (c) 4 x 15 mg/m2... 
Pharmacokinetics | Doxorubicin | Schedule dependence | Dose-Response Relationship, Drug | Drug Administration Schedule | Humans | Middle Aged | Adolescent | Child, Preschool | Adult | Female | Male | Child | Doxorubicin - pharmacokinetics | Doxorubicin - administration & dosage
Journal Article